About Us
Leading the way in drug development for lysosomal ion-channels
Lysoway Therapeutics is pioneering the field of lysosomal ion-channel biology and next-generation drug discovery.
Using our proprietary screening platforms and structure-guided design technologies, we develop highly brain-penetrant, selective, and potent small-molecule modulators targeting key lysosomal ion channels such as TRPML1 and TMEM175.
These ion channels are essential regulators of intracellular signaling and play a central role in maintaining lysosomal health and autophagic flux—critical processes that often break down in age-related neurodegenerative diseases and lysosomal storage disorders.
By precisely restoring lysosomal function and rebalancing autophagy, Lysoway’s therapeutics aim to correct the core cellular defects that drive these conditions and unlock new possibilities for meaningful patient impact.
Leadership Team
Discovery Research
Board of Directors
Our Investors
By working closely with trusted collaborators across the industry, we strengthen our research pipeline and deliver measurable value at every stage of development.
